Event focused on cross-border deals between the U.S. and China in the health sciences sector to be held January 8, 2019 in San Francisco, coinciding with 37th Annual J.P. Morgan Healthcare Conference
New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that the company will participate in a panel discussion, “Innovation Across Borders: Strategies for U.S. and Chinese Companies in the Health Sciences Industry,” to be hosted by Duane Morris LLP and the Chinese Biopharmaceutical Association (USA) on Tuesday, January 8, 2019 in San Francisco, CA. The timing of the meeting coincides with the 37th Annual J.P. Morgan Healthcare Conference being held in San Francisco January 7-10, 2019.
Nicolas G. Sitchon, chief executive officer of S1, will present a company overview and outline S1’s strategy to develop investment opportunities and industry collaborations and partnerships with industry leaders and investors in China. The panel discussion will take place from 7:30 a.m. to 11:00 a.m. PST at the Duane Morris office located at One Market Plaza (Suite 2200) in San Francisco.
“Collaboration with industry leaders and investors in the life sciences sector in China continues to present multiple opportunities for U.S. companies, and this discussion will highlight the rapidly emerging trends and regulatory and legal considerations that can make these collaborations especially advantageous for S1 Biopharma and other innovative companies in the years ahead,” said Mr. Sitchon.
For more information visit https://www.duanemorris.com/events/innovation_across_borders_strategies_for_us_chinese_companies_in_health_sciences_1218.html.
About S1 Biopharma, Inc.
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company’s development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company’s lead product candidate, Lorexys, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally. For more information, visit http://s1biopharma.com/ or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).
Berry & Company Public Relations